Table 3.

Percentage of Patients (95% CI) With 2-Hour Freedom From Migraine Associated Symptoms in the Ketorolac vs Sumatripan vs Placebo Nasal Spray Migraine Study

	Placebo % (95% CI)	Ketorolac NS % (95% CI)	P-Value* vs Placebo	Sumatriptan NS % (95% CI)	P-Value vs Placebo	P-Value vs Ketorolac
No phonophobia, 2 hrs	56.0 (46.1–65.9)	75.0 (66.5–83.4)	.007	66.0 (56.5–75.4)	.091	.278
No photophobia, 2 hrs	46.0 (36.1–55.9)	65.4 (56.1–74.7)	.016	64.0 (54.4–73.6)	.011	.848
No nausea, 2 hrs	66.0 (56.5–75.4)	82.7 (75.3–90.0)	.036	74.0 (65.2–82.7)	.317	.267
No allodynia, 2 hrs	69.0 (57.6–83.5)	70.5 (57.6–83.5)	.477	75.5 (63.0–87.9)	.373	.538

^*P-values computed using a mixed longitudinal model; hrs =hours.